STDUY PROTOCOL
EVALUATION OF ANALGESIC
POTENTIAL OF TEST COMPOUND(S) USING TAIL FLICK TEST IN EXPERIMENTAL ANIMALS
1.0 INTRODUCTION
Species
: Mus musculus
Strain : Swiss albino
Age : 6-10 weeks
Body
Wight : 20-25 g
Sex : Male
No. of
animals : 8/Group
Groups |
Treatment |
Dose; ROA |
No. of Animals |
G1 |
Normal
Control |
Normal
saline or 0.25% Na-CMC |
8 |
G2 |
Reference
Drug- Indomethacin |
10
mpk; p.o. |
8 |
G3 |
Test
Compound-I |
X
mpk; p.o. |
8 |
G4 |
Test
Compound-I |
XX
mpk; p.o. |
8 |
G5 |
Test
Compound-II |
X
mpk; p.o. |
8 |
G6 |
Test
Compound-II |
XX
mpk; p.o. |
8 |
Extra 5 animals will be taken considering animal screening
based on the basal latency time
3.0 METHOD:
· Animals shall be procured from the CPCSEA authorized vendor.
· Animals shall be quarantined for 1 week as per the in house SOP.
· Healthy animals will be selected, randomized based on body weight and divided into 6 different groups consisting of 8 animals each.
· Group G1 animal will be treated as normal control and treated with normal saline or Na- CMC.
· Animals of group G2 will be treated orally with indomethacin at the dose of 10mpk, p.o.
· Group G3, G4, G5 and G6 animals will be treated with test compound at different dose levels.
· Thirty minutes later, a radiant heat, automatic tail flick algesiometer will be used to measure response latencies.
· The light beam will be focused on the animal’s tail about 4 cm from the tip and the intensity will be adjusted so that baseline readings will be between 2 and 3s.
· An 8 s cut-off time (Toff) will be imposed to avoid damage to the tail.
· After 30 min of the drug treatment, all the animals will be subjected to the tail flick latency measurement at 60, 120, 280 min.
· The number of tail flick latency of the test groups at different dose levels, and standard will be compared with the control.
5.0 END POINT PARAMETER(S):
· No. Tail flick latencies
· % Maximum Possible Effect = 100 X(L2-L1)/(Toff- L1)
where L2 is the post drug latency and L1 is the pre drug latency or control reaction time.
6.0 REFERENCE(S):
5.1 Sylvia Arraua, Carla Delportea, Carlos Cartagenaa, Maité Rodríguez-Díaz a, Patricia González b, Ximena Silva b, Bruce K. Cassels c, Hugo F. Miranda d. Antinociceptive activity of Quillaja saponaria Mol. saponin extract, quillaic acid and derivatives in mice. Journal of Ethnopharmacology 133 (2011) 164–167.
5.2 Le Bars, D. Gozariu, M. Cadden, S.W. 2001. Animal models of nociception. Pharmacology Review 53, 597–652.
END OF DOCUMENT
0 comments:
Post a Comment